

FAX RECEIVED

DEC 03 2002

GROUP 1600

Please type a plus sign (+) inside this box → ☒PTO/SB/21 (8-98)  
Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	09/889,106	
	Filing Date	July 11, 2001	
	First Named Inventor	Haile Tecle, et al.	
	Group Art Unit	1626	
	Examiner Name	Golam M. Shameem	
Total Number of Pages in This Submission	8	Attorney Docket Number	5940-01-SMH

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/89) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Certificate of Transmission
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Suzanne M. Harvey
Signature	<i>Suzanne M. Harvey</i>
Date	December 2, 2002

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>	
Typed or printed name	<input type="text"/>
Signature	<input type="text"/>
Date	<input type="text"/>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

5940-01-SMH

## IN THE UNITED STATES PATENT &amp; TRADEMARK OFFICE

APPLICANT : Haile Tecle, et al.

EXAMINER : Golam M. Shameem

SERIAL NO. : 09/889,106

ART UNIT : 1626

FILED : July 11, 2001

PAPER NO. : 5

FOR : 4' HETEROARYL DIARYLAMINES

## Response to Restriction Requirement Under 35 U.S.C. 121 and 372

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

12/16/2002 RHARMON 00000002 230455 09889106

01 FC:1251 110.00 C This is in response to the Office Action dated September 30, 2002 (Paper Number 4) in which Restriction was required under 35 U.S.C. 121 and 372.

Under PCT Rule 13.1 and in accordance with 37 CFR 1.499, Applicants were required to elect a single invention of the following inventions:

**Group I**, claim(s) 1-29, drawn to a compound of the formula (I) wherein,  $R_1$  is heterocyclic radical (such as pyrrole, pyrazole),  $R_2$  and  $R_3$  is independently H, phenyl,  $C_{1-4}$  alkyl,  $C_{3-8}$  alkynyl,  $C_{3-8}$  cycloalkyl,  $R_4$ ,  $R_5$ , and  $R_6$ , is independently H, CL, F, or Br,  $R_A$  and  $J$  are heterocyclic radical (such as pyrrole, pyrazole),  $R_C$ ,  $R_D$ ,  $R_E$ ,  $R_F$  and  $R_G$  is independently selected from pyrrolidinyl and all other variable substitutions are as defined and one method of use (e.g. treating cancer);

**Group II**, claim(s) 1-29, drawn to a compound of the formula (I) wherein,  $R_1$  is heterocyclic radical (such as morpholinyl, pyrazinyl),  $R_2$  and  $R_3$  is independently H, phenyl,  $C_{1-4}$  alkyl,  $C_{3-8}$  alkynyl,  $C_{3-8}$  cycloalkyl,  $R_4$ ,  $R_5$  and  $R_6$  is independently H, CL, F, or Br,  $R_A$  and  $J$

5940 US Response Restriction Requirement

Received from &lt;7346222928&gt; at 12/2/02 3:04:58 PM [Eastern Standard Time]

09/889,106

-2-

5940-01-SMH

are heterocyclic radical (such as morpholinyl, pyrazinyl),  $R_C$ ,  $R_D$ ,  $R_E$ ,  $R_F$  and  $R_G$  is independently selected from pyrazinyl and all other variable substitutions are as defined and one method of use (e.g. treating septic shock);

**Group III**, claim(s) 1-29, drawn to a compound of the formula (I) wherein,  $R_1$  is non-heterocyclic radical (such as H,  $C_{1-8}$  alkyl,  $C_{3-8}$  alkenyl,  $C_{3-8}$  alkynyl, phenyl,  $C_{3-8}$  cycloalkyl etc.),  $R_2$  and  $R_3$  is independently H, phenyl,  $C_{1-4}$  alkyl,  $C_{3-8}$  alkynyl,  $C_{3-8}$  cycloalkyl,  $R_4$ ,  $R_5$  and  $R_6$  is independently H, CL, F, or Br,  $R_A$  and J are non-heterocyclic radical (such as H,  $C_{1-6}$  alkyl,  $C_{3-8}$  alkenyl,  $C_{3-8}$  alkynyl, phenyl,  $C_{3-8}$  cycloalkyl etc.),  $R_C$ ,  $R_D$ ,  $R_E$ ,  $R_F$  and  $R_G$  is independently selected from non-heterocyclic radical (such as H,  $C_{1-6}$  alkyl,  $C_{3-8}$  alkenyl,  $C_{3-8}$  alkynyl, phenyl,  $C_{3-8}$  cycloalkyl etc.) and all other variable substitutions are as defined and one method of use (e.g. treating cystic fibrosis);

**Group IV**, claims 30-48, drawn to a method for treating a disease with the compound of the formula (I) wherein,  $R_1$  is heterocyclic radical (such as pyrrole, pyrazole),  $R_2$  and  $R_3$  is independently H, phenyl,  $C_{1-4}$  alkyl,  $C_{3-8}$  alkynyl,  $C_{3-8}$  cycloalkyl,  $R_4$ ,  $R_5$  and  $R_6$  is independently H, CL, F, or Br,  $R_A$  and J are heterocyclic radical (such as pyrrole, pyrazole),  $R_C$ ,  $R_D$ ,  $R_E$ ,  $R_F$  and  $R_G$  is independently selected from pyrrolidinyl and all other variable substitutions are as defined heterocyclic radical and all other variable substitutions are as defined;

**Group V**, claims 30-48, drawn to a method for treating a disease with the compound of the formula (I) wherein,  $R_1$  is heterocyclic radical (such as morpholinyl, pyrazinyl),  $R_2$  and  $R_3$  is independently H, phenyl,  $C_{1-4}$  alkyl,  $C_{3-8}$  alkynyl,  $C_{3-8}$  cycloalkyl,  $R_4$ ,  $R_5$  and  $R_6$  is independently H, CL, F, or Br,  $R_A$  and J are heterocyclic radical (such as morpholinyl, pyrazinyl),  $R_C$ ,  $R_D$ ,  $R_E$ ,  $R_F$  and  $R_G$  is independently selected from pyrazinyl and all other variable substitutions are as defined;

09/889,106

-3-

5940-01-SMH

**Group VI**, claims 30-48, drawn to a compound of the formula (I) wherein,  $R_1$  is non-heterocyclic radical (such as H,  $C_{1-8}$  alkyl,  $C_{3-8}$  alkenyl,  $C_{3-8}$  alkynyl, phenyl,  $C_{3-8}$  cycloalkyl etc.),  $R_2$  and  $R_3$  is independently H, phenyl,  $C_{1-4}$  alkyl,  $C_{3-8}$  alkynyl,  $C_{3-8}$  cycloalkyl,  $R_4$ ,  $R_5$  and  $R_6$  is independently H, CL, F, or Br,  $R_A$  and J are non-heterocyclic radical (such as H,  $C_{1-6}$  alkyl,  $C_{3-8}$  alkenyl,  $C_{3-8}$  alkynyl, phenyl,  $C_{3-8}$  cycloalkyl etc.),  $R_C$ ,  $R_D$ ,  $R_E$ ,  $R_F$  and  $R_G$  is independently selected from non-heterocyclic radical (such as H,  $C_{1-6}$  alkyl,  $C_{3-8}$  alkenyl,  $C_{3-8}$  alkynyl, phenyl,  $C_{3-8}$  cycloalkyl etc.) and all other variable substitutions are as defined;

**Group VII**, claims 49-50, drawn to a method for treating a disease with chemotherapy using the compound of the formula (I) wherein,  $R_1$  is heterocyclic radical (such as pyrrole, pyrazole),  $R_2$  and  $R_3$  is independently H, phenyl,  $C_{1-4}$  alkyl,  $C_{3-8}$  alkynyl,  $C_{3-8}$  cycloalkyl,  $R_4$ ,  $R_5$  and  $R_6$  is independently H, CL, F, or Br,  $R_A$  and J are heterocyclic radical (such as pyrrole, pyrazole),  $R_C$ ,  $R_D$ ,  $R_E$ ,  $R_F$  and  $R_G$  is independently selected from pyrrolidinyl and all other variable substitutions are as defined;

**Group VIII**, claims 49-50, drawn to a method for treating a disease with chemotherapy using the compound of the formula (I) wherein,  $R_1$  is heterocyclic radical (such as morpholinyl, pyrazinyl),  $R_2$  and  $R_3$  is independently H, phenyl,  $C_{1-4}$  alkyl,  $C_{3-8}$  alkynyl,  $C_{3-8}$  cycloalkyl,  $R_4$ ,  $R_5$  and  $R_6$  is independently H, CL, F, or Br,  $R_A$  and J are heterocyclic radical (such as morpholinyl, pyrazinyl),  $R_C$ ,  $R_D$ ,  $R_E$ ,  $R_F$  and  $R_G$  is independently selected from pyrazinyl and all other variable substitutions are as defined; or

**Group IX**, claims 49-50, drawn to a method for treating a disease with chemotherapy using the compound of the formula (I) wherein,  $R_1$  is non-heterocyclic radical (such as H,  $C_{1-8}$  alkyl,  $C_{3-8}$  alkenyl,  $C_{3-8}$  alkynyl, phenyl,  $C_{3-8}$  cycloalkyl etc.),  $R_2$  and  $R_3$  is independently H, phenyl,  $C_{1-4}$  alkyl,  $C_{3-8}$  alkynyl,  $C_{3-8}$  cycloalkyl,  $R_4$ ,  $R_5$  and  $R_6$  is independently H, CL, F, or Br,  $R_A$  and J are non-heterocyclic radical (such as H,  $C_{1-6}$  alkyl,  $C_{3-8}$  alkenyl,  $C_{3-8}$  alkynyl, phenyl,  $C_{3-8}$  cycloalkyl etc.),  $R_C$ ,  $R_D$ ,  $R_E$ ,  $R_F$  and  $R_G$  is independently selected from non-heterocyclic

09/889,106

-4-

5940-01-SMH

radical (such as H, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> alkenyl, C<sub>3-8</sub> alkynyl, phenyl, C<sub>3-8</sub> cycloalkyl etc.) and all other variable substitutions are as defined.

The Applicants hereby elect Group III for prosecution on the merits, without traverse.  
The Applicant hereby select the treatment of cancer as the one method of use to accompany the compounds of Group III. Finally, the Applicants respectfully reserve the right to file a Divisional application(s) to the non-elected claims.

The Applicants submit that this application is now in condition for allowance, which allowance is respectfully solicited.

Respectfully submitted,

Dated:

December 2, 2002

Suzanne M. Harvey

Suzanne M. Harvey  
Registration No. 42,640  
Warner-Lambert Company  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Telephone: (734) 622-2658  
Facsimile: (734) 622-1553